Quantra vs TEG for Congenital Cardiac Surgery - a Pilot Validation Study

Not Recruiting

Trial ID: NCT05295693


Congenital heart surgery on cardio-pulmonary bypass (CPB) is associated with impacted coagulation quality and increased bleeding after separation of CPB. The current testing device used at our institution is the "TEG 5000" (Haemonetics Corporation). The novel coagulation testing device "Quantra System" (Hemosonics) has favorable properties (result within 20 minutes) allowing for a quicker identification of the coagulation problem and hence faster administration of the correct coagulation products, potentially leading to better coagulation quality and possibly reducing the need of additional blood products. The aim of this prospective observational (non-interventional, investigational only) quality improvement study is to investigate if the Quantra is reliable and valid in predicting the coagulation status when compared with our standard-of-care device TEG 5000.

Official Title

Comparison of the Point-of-care Coagulation Device Quantra With the TEG for Congenital Cardiac Surgery - a Pilot Validation Study

Stanford Investigator(s)

Alexander Robert Schmidt

Clinical Associate Professor, Anesthesiology, Perioperative and Pain Medicine


Inclusion Criteria:

   - All cases with hypothermia (<=30C)

Exclusion Criteria:

   - Neonatal/Infant Bloodless surgery

   - Bodyweight under 3kg


device: Correlation of the Quantra with the TEG

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Alexander R Schmidt, MD